Clinical study of regorafenib combined with PD-1/PD-L1 monoclonal antibody and local c-TACE in the treatment of MSS advanced colorectal cancer with liver metastasis

Interventions: one:Interventional protocol: regorafenib and PD-1/PD-L1 treatment within 1 week before liver c-TACE, intraoperative administration: raltitrexed 4mg.
Primary outcome(s): Objective Response Rate, ORR
Study Design: Single arm

干预措施：干预方案为于肝脏常规经动脉化疗栓塞（c-TACE）术前1周内给予瑞戈非尼（regorafenib）及PD-1/PD-L1抑制剂治疗，术中给药剂量为雷替曲塞（raltitrexed）4mg。主要结局指标：客观缓解率（Objective Response Rate，ORR）。研究设计：单臂试验。